In late 2020, after circulating for almost a year in the human population, severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibited a major step change in its …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
deaths and substantial morbidity worldwide. Intense scientific effort to understand the …

Abstract Three lineages (BA. 1, BA. 2 and BA. 3) of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) Omicron variant of concern predominantly drove South Africa's …

The first dominant SARS‐CoV‐2 Omicron variant BA. 1 harbours 35 mutations in its Spike
protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its …

Background Nirmatrelvir–ritonavir has been authorized for emergency use by many
countries for the treatment of coronavirus disease 2019 (Covid-19). However, the supply …

Objectives To characterize the clinical severity of covid-19 associated with the alpha, delta,
and omicron SARS-CoV-2 variants among adults admitted to hospital and to compare the …

Having adopted a dynamic zero-COVID strategy to respond to SARS-CoV-2 variants with
higher transmissibility since August 2021, China is now considering whether, and for how …

Neutralization of Omicron BA. 1 and BA. 2 Variants Although two doses of BNT162b2
vaccine produce immunity that wanes over time, the administration of a booster dose …

Abstract The SARS-CoV-2 Omicron BA. 1 variant emerged in 2021 and has multiple
mutations in its spike protein. Here we show that the spike protein of Omicron has a higher …

Monoclonal antibodies (mAbs) offer a treatment option for individuals with severe COVID-19
and are especially important in high-risk individuals where vaccination is not an option …